transmembrane protein 176BGenealiases: LR8 · MS4B2
Q-omics provides the consensus-scored TMEM176B profile across patient tissues and cancer cell-line models. TMEM176B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TMEM176B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TMEM176B protein abundance shows 21,532 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where TMEM176B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM176B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM176B survival associations across molecular data types. TMEM176B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM176B RNA expression–survival associations across cancer types. High TMEM176B expression shows unfavorable associations in LGG, but favorable associations in SKCM, KIRC, HNSC, KIRP and SARC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TMEM176B RNA expression.
This table summarizes TMEM176B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM176B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM176B shows lower tumor expression in KICH and BRCA and higher tumor expression in KIRC, STAD, THCA and LUAD. The KIRC box plot shows higher TMEM176B RNA expression in tumor versus normal tissue (log2 FC = +1.354, t-test p < 0.001).
This table shows molecular features associated with TMEM176B in patient tissues and cancer cell lines. In patient samples, TMEM176B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM176B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
